We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) along with Germany’s Merck KGaA announced that the European Commission (“EC”) has approved their PD-L1 inhibitor, Bavencio (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced/metastatic urothelial carcinoma (“UC”) who remain progression-free following platinum-based chemotherapy.
We note that Bavencio is already approved for patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or in other words, for second-line use.
The approval in EU for this expanded indication was based on data from the phase III JAVELIN Bladder 100 study which evaluated Bavencio plus best supportive care (“BSC”) in the given patient population.
Data from the study showed that Bavencio as first-line maintenance treatment led to a significant improvement in median overall survival (“OS”) versus BSC alone. Per the company, Bavencio is the first and only immunotherapy to demonstrate a significant OS benefit in the first-line setting in a phase III study for advanced/metastatic UC, the most common form of bladder cancer.
Based on the above data, the Bavencio first-line maintenance regimen has been recommended for use by the ESMO Bladder Cancer Guidelines.
Per the press release, despite available treatments, an estimated 204,000 people were diagnosed with bladder cancer across Europe in 2020, which resulted in more than 67,000 deaths from the disease. The five-year survival rate is 5% for patients diagnosed with metastatic UC.
Hence, following the approval by the EC, Bavencio can now be given to patients as a potential new first-line maintenance standard of care.
Bavencio was approved in the United States for first-line maintenance treatment for advanced UC in June last year.
Additionally, Bavnecio is approved for use in combination with Pfizer’s Inlyta for first-line treatment of advanced kidney cancer and for Merkel cell carcinoma. Although Bavencio is currently approved for three relatively smaller indications, it might emerge as a key long-term driver for Pfizer on future label-expansion approvals.
However, Bavencio faces stiff competition from other approved PD-L1 inhibitors in the market, such as Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab), Bristol-Myers’ (BMY - Free Report) Opdivo (nivolumab) and AstraZeneca’s (AZN - Free Report) Imfinzi (durvalumab).
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer
Pfizer Inc. (PFE - Free Report) along with Germany’s Merck KGaA announced that the European Commission (“EC”) has approved their PD-L1 inhibitor, Bavencio (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced/metastatic urothelial carcinoma (“UC”) who remain progression-free following platinum-based chemotherapy.
We note that Bavencio is already approved for patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or in other words, for second-line use.
The approval in EU for this expanded indication was based on data from the phase III JAVELIN Bladder 100 study which evaluated Bavencio plus best supportive care (“BSC”) in the given patient population.
Data from the study showed that Bavencio as first-line maintenance treatment led to a significant improvement in median overall survival (“OS”) versus BSC alone. Per the company, Bavencio is the first and only immunotherapy to demonstrate a significant OS benefit in the first-line setting in a phase III study for advanced/metastatic UC, the most common form of bladder cancer.
Based on the above data, the Bavencio first-line maintenance regimen has been recommended for use by the ESMO Bladder Cancer Guidelines.
Per the press release, despite available treatments, an estimated 204,000 people were diagnosed with bladder cancer across Europe in 2020, which resulted in more than 67,000 deaths from the disease. The five-year survival rate is 5% for patients diagnosed with metastatic UC.
Hence, following the approval by the EC, Bavencio can now be given to patients as a potential new first-line maintenance standard of care.
Bavencio was approved in the United States for first-line maintenance treatment for advanced UC in June last year.
Additionally, Bavnecio is approved for use in combination with Pfizer’s Inlyta for first-line treatment of advanced kidney cancer and for Merkel cell carcinoma. Although Bavencio is currently approved for three relatively smaller indications, it might emerge as a key long-term driver for Pfizer on future label-expansion approvals.
However, Bavencio faces stiff competition from other approved PD-L1 inhibitors in the market, such as Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab), Bristol-Myers’ (BMY - Free Report) Opdivo (nivolumab) and AstraZeneca’s (AZN - Free Report) Imfinzi (durvalumab).
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>